SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *

Herr Amy E.

(Last) (First) (Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading Symbol

BIO-TECHNE Corp [TECH]

3. Date of Earliest Transaction (Month/Day/Year)

10/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

X Director — 10% Owner

Officer (give title below) — Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								576	I	By significant other
Common Stock	10/29/2026		A		2,750	A	$0	5,430	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	$66.97							(1)	08/05/2027	Common Stock	4,472		4,472	I	By significant other
Stock Option (Right to Buy)	$120.46							(1)	08/06/2028	Common Stock	2,076		2,076	I	By significant other
Stock Option (Right to Buy)	$94.52							(1)	08/15/2029	Common Stock	2,104		2,104	I	By significant other
Stock Option (Right to Buy)	$84.61							(2)	08/15/2030	Common Stock	1,084		1,084	I	By significant other
Stock Option (Right to Buy)	$74.91							(3)	08/15/2034	Common Stock	1,468		1,468	I	By significant other
Stock Option (Right to Buy)	$72.05							(1)	02/03/2035	Common Stock	2,415		2,415	D	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	$72.05							(4)	02/03/2035	Common Stock	344		344	I	By significant other
Stock Option (Right to Buy)	$53.6							(5)	08/15/2035	Common Stock	2,735		2,735	I	By significant other
Stock Option (Right to Buy)	$60.96							(1)	10/30/2035	Common Stock	3,777		3,777	D	
Restricted Stock Units	(6)							(7)	(7)	Common Stock	160		160	I	By significant other
Restricted Stock Units	(6)							(8)	(8)	Common Stock	77		77	I	By significant other
Restricted Stock Units	(6)							(9)	(9)	Common Stock	621		621	I	By significant other
Restricted Stock Units	(6)							(10)	(10)	Common Stock	1,381		1,381	I	By significant other

Explanation of Responses:

1. Fully vested.
2. Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
3. Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
4. Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
5. Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
6. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
7. 160 restricted stock units vest on 8/15/2027.
8. 38 restricted stock units vest on 2/3/2027, and 39 restricted stock units vest on 2/3/2028.
9. 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.
10. 460 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 461 restricted stock units vest on 8/17/2029.

/s/ Andrew Nick as Attorney-in-Fact for Amy E. Herr pursuant to Power of Attorney previously filed — 11/02/2026

** Signature of Reporting Person — Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.